FDA warning letter · Drugs

Beeyoutiful.com, LLC

Issued · Posted by FDA

FDA published a close-out letter on Jun 10, 2022. The passages below are from the original warning letter.

Selected passages from the FDA letter

Quoted FDA text from the published dataset. These selected excerpts are not the complete letter.

Passage 1

Your Vitex w/ Dong Quai, Berry Well, Cranberry Power Cleanse, Tummy Tuneup, Colostrum Transfer Factor, Methylated Folate, Prostate Health—Clinical Strength, D3, Vitamin K2 + D3, Dino Bones, Dynamic Duo A + D, Liquid D3, B-Better, Gentle C, CoQ10, Glucosamine/MSM, Bone Ami, Bio B12, Liquid B12, Bromelain, Magnesium Citrate, Omega-3, Odorless Garlic, Selenium Secure, Biome Blast (Yeast Assassin), and Caprylic Acid products are not generally recognized as safe and effective for the above-referenced uses and therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)].

Passage 2

Your Vitex w/ Dong Quai, Berry Well, Cranberry Power Cleanse, Tummy Tuneup, Colostrum Transfer Factor, Prostate Health—Clinical Strength, D3, Vitamin K2 + D3, Dino Bones, Dynamic Duo A + D, Liquid D3, Gentle C, CoQ10, Bio B12, Liquid B12, Bromelain, Magnesium Citrate, Omega-3, Odorless Garlic, Selenium Secure, and Biome Blast (Yeast Assassin) products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, your Vitex w/ Dong Quai, Berry Well, Cranberry Power Cleanse, Tummy Tuneup, Colostrum Transfer Factor, Prostate Health—Clinical Strength, D3, Vitamin K2 + D3, Dino Bones, Dynamic Duo A + D, Liquid D3, Gentle C, CoQ10, Bio B12, Liquid B12, Bromelain, Magnesium Citrate, Omega-3, Odorless Garlic, Selenium Secure, and Biome Blast (Yeast Assassin) fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)].

Citations in the original letter

As cited in this historical letter, not a statement of current regulatory requirements.

  • 21 CFR 201.5